scispace - formally typeset
E

Eva Harris

Researcher at University of California, Berkeley

Publications -  357
Citations -  26475

Eva Harris is an academic researcher from University of California, Berkeley. The author has contributed to research in topics: Dengue virus & Dengue fever. The author has an hindex of 84, co-authored 332 publications receiving 22718 citations.

Papers
More filters
Journal ArticleDOI

Early Clinical Features of Dengue Virus Infection in Nicaraguan Children: A Longitudinal Analysis

TL;DR: Day-by-day analysis of clinical signs and symptoms together with longitudinal statistical analysis showed significant associations with testing dengue-positive and important differences during the early phase of illness compared to the entire course of illness.
Journal ArticleDOI

Endocytosis of flavivirus NS1 is required for NS1-mediated endothelial hyperpermeability and is abolished by a single N-glycosylation site mutation.

TL;DR: The N207 glycosylation site is highly conserved among flaviviruses and is also essential for West Nile and Zika virus NS1 to trigger endothelial hyperpermeability via clathrin-mediated endocytosis, providing critical mechanistic insight into flavivirus NS1-induced pathogenesis.
Journal ArticleDOI

S-Phase-Dependent Enhancement of Dengue Virus 2 Replication in Mosquito Cells, but Not in Human Cells

TL;DR: A differential response of DEN2 to the mosquito and human cell cycle is demonstrated and analysis of viral RNA and protein released from the cells indicated that enhanced DEN2 assembly is largely responsible for increased virus titers produced during S-phase.
Journal ArticleDOI

FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies.

TL;DR: Results argue against a role for FcγRs in IgG transplacental transport, suggesting Fc engineering of maternally administered antibody to enhance only FcRn binding as a means to improve maternal-fetal transport of IgG.
Journal ArticleDOI

Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge.

TL;DR: To better understand the humoral responses and correlates of protection (CoP) induced by the VLP vaccine, evaluated VLP immunogenicity with and without alum in immune-competent mice and observed efficient induction of neutralizing antibody as well as a dose-sparing effect of alum.